SynthesisAntimicrobial agents and chemotherapy2021
Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.
Synthesis in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Tuberculous Meningitis in Pediatric Patients: Diagnosis, Clinical Course, and Outcomes in the Modern Era.Pathogens (Basel, Switzerland) · 2026Observational
- Routine Molecular Surveillance of Drug-Resistant Tuberculosis: Translating Mutation Proxies into Clinical Governance Intelligence in Rural Eastern Cape.Healthcare (Basel, Switzerland) · 2026Article
- Pattern and prevalence of rifampicin and isoniazid-resistant tuberculosis using genotype MTBDRMicrobiology spectrum · 2026Article
- Prevalence and profile of isoniazid mono-resistant tuberculosis in Pakistan: Insights from a decade of surveillance.Pakistan journal of medical sciences · 2026Article
- Multidrug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: Clinical, Bacteriological, and Programmatic Predictors of Poor Treatment Outcomes.Microorganisms · 2026Article
- The potential of molecular testing and mutation analysis for detecting isoniazid and rifampicin-resistant Mycobacterium tuberculosis in Thailand.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- From mutation detection to treatment decisions: CRISPR-enabled diagnostics for drug-resistant tuberculosis.Frontiers in bioengineering and biotechnology · 2026Review
- Challenges and Potential of Antibody-Drug Conjugates as Prospective Tuberculosis Therapeutics.Microorganisms · 2025Review
- Fitness Effect of the Isoniazid Resistance Mutation S315T of the Catalase-Peroxidase Enzyme KatG of Mycobacterium tuberculosis.Genome biology and evolution · 2025Article
- The Identification of Novel Mutations in ATP-Dependent Protease ClpC1 Assists in the Molecular Diagnosis of Obscured Pyrazinamide-Resistant Tuberculosis Clinical Isolates.Microorganisms · 2025Article
- Prevalence of katG and inhA mutations associated with isoniazid resistance in Mycobacterium tuberculosis clinical isolates in Cameroon.BMC microbiology · 2025Article
- Article
- Catalase-peroxidase (KatG): a potential frontier in tuberculosis drug development.Critical reviews in biochemistry and molecular biology · 2024Review
- Differential Host Gene Expression in Response to Infection by DifferentMicroorganisms · 2024Article
- Case Report: Disseminated Tuberculosis After Kidney Transplantation.The American journal of tropical medicine and hygiene · 2024Article
- The Detection of Mutations and Genotyping of Drug-ResistantInfectious disease reports · 2023Article
- Insight into Population Structure and Drug Resistance of Pediatric Tuberculosis Strains from China and Russia Gained through Whole-Genome Sequencing.International journal of molecular sciences · 2023Article
- Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023Article
- Deciphering Isoniazid Drug Resistance Mechanisms on DimericACS omega · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular testing is rapidly becoming an integral component of global tuberculosis (TB) control. Uncommon mechanisms of resistance escape detection by these platforms and undermine our ability to contain outbreaks. This article is a systematic review of published articles that reported isoniazid (INH) resistance-conferring mutations between September 2013 and December 2019. The genes
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.